[go: up one dir, main page]

TNSN96016A1 - Utilisation de phenylcyclohexylcarboxamides - Google Patents

Utilisation de phenylcyclohexylcarboxamides

Info

Publication number
TNSN96016A1
TNSN96016A1 TNTNSN96016A TNSN96016A TNSN96016A1 TN SN96016 A1 TNSN96016 A1 TN SN96016A1 TN TNSN96016 A TNTNSN96016 A TN TNSN96016A TN SN96016 A TNSN96016 A TN SN96016A TN SN96016 A1 TNSN96016 A1 TN SN96016A1
Authority
TN
Tunisia
Prior art keywords
phenylcyclohexylcarboxamides
medicinal products
restenosis
treatment
active ingredients
Prior art date
Application number
TNTNSN96016A
Other languages
English (en)
Inventor
Matthias Muller-Gliemann Dr
Ulrich Muller Dr
Martin Beuck Dr
Siegfried Zaiss Dr
Christoph Gerdes Dr
Anke Domdey-Bette Dr
Rudi Grutzmann Dr
Stefan Lohmer Dr
Stefan Wohlfeil Dr
Ozkan Yalkinoglu Dr
James Elting Dr
Dirk Denzer Dr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of TNSN96016A1 publication Critical patent/TNSN96016A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LES PHENYLCYCLOHEXYLCARBOXAMIDES, DONT QUELQUES UNS SONT CONNUS, CONVIENNENT COMME PRINCIPES ACTIFS DANS DES MEDICAMENTS, EN PARTICULIER DANS DES MEDICAMENTS DESTINES AU TRAITEMENT DE LA RESTENOSE
TNTNSN96016A 1995-02-01 1996-02-01 Utilisation de phenylcyclohexylcarboxamides TNSN96016A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19503160A DE19503160A1 (de) 1995-02-01 1995-02-01 Verwendung von Phenylcyclohexylcarbonsäureamiden

Publications (1)

Publication Number Publication Date
TNSN96016A1 true TNSN96016A1 (fr) 2005-03-15

Family

ID=7752849

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96016A TNSN96016A1 (fr) 1995-02-01 1996-02-01 Utilisation de phenylcyclohexylcarboxamides

Country Status (31)

Country Link
US (1) US5935983A (fr)
EP (1) EP0725064A1 (fr)
JP (1) JPH08253453A (fr)
KR (1) KR960031442A (fr)
CN (1) CN1137380A (fr)
AR (1) AR002272A1 (fr)
AU (1) AU710235B2 (fr)
BG (2) BG103820A (fr)
CA (1) CA2168317A1 (fr)
CZ (1) CZ29196A3 (fr)
DE (1) DE19503160A1 (fr)
DZ (1) DZ1986A1 (fr)
EE (1) EE9600023A (fr)
FI (1) FI960425L (fr)
HR (1) HRP960017A2 (fr)
HU (1) HUP9600227A3 (fr)
IL (1) IL116931A (fr)
MA (1) MA23794A1 (fr)
NO (1) NO309841B1 (fr)
NZ (1) NZ280905A (fr)
PL (1) PL312546A1 (fr)
RO (1) RO117256B1 (fr)
RU (1) RU2158261C2 (fr)
SG (1) SG42329A1 (fr)
SK (1) SK13796A3 (fr)
SV (1) SV1996000008A (fr)
TN (1) TNSN96016A1 (fr)
TW (1) TW448176B (fr)
UA (1) UA35623C2 (fr)
YU (1) YU5896A (fr)
ZA (1) ZA96725B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
DE19924818A1 (de) 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide
DE19924819A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
US6934951B2 (en) 2002-01-17 2005-08-23 Intel Corporation Parallel processor with functional pipeline providing programming engines by supporting multiple contexts and critical section
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
FR2852957B1 (fr) * 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AU2004263190A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4224133A1 (de) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4226109A1 (de) * 1992-08-07 1994-02-10 Bayer Ag Verwendung von ASS zur Hemmung von Plaquebildung
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe

Also Published As

Publication number Publication date
TW448176B (en) 2001-08-01
HRP960017A2 (en) 1997-12-31
HUP9600227A2 (en) 1996-12-30
NO960414L (no) 1996-08-02
EE9600023A (et) 1996-08-15
FI960425A7 (fi) 1996-08-02
RU2158261C2 (ru) 2000-10-27
IL116931A0 (en) 1996-05-14
SV1996000008A (es) 1996-11-04
BG103820A (bg) 2001-09-28
CA2168317A1 (fr) 1996-08-02
AR002272A1 (es) 1998-03-11
IL116931A (en) 2000-06-01
MA23794A1 (fr) 1996-10-01
DE19503160A1 (de) 1996-08-08
CZ29196A3 (en) 1996-08-14
JPH08253453A (ja) 1996-10-01
RO117256B1 (ro) 2001-12-28
NZ280905A (en) 1996-12-20
NO309841B1 (no) 2001-04-09
CN1137380A (zh) 1996-12-11
BG63044B1 (bg) 2001-02-28
FI960425L (fi) 1996-08-02
SG42329A1 (en) 1997-08-15
NO960414D0 (no) 1996-01-31
AU4224096A (en) 1996-08-08
YU5896A (sh) 1998-12-23
US5935983A (en) 1999-08-10
FI960425A0 (fi) 1996-01-30
ZA96725B (en) 1996-08-20
BG100326A (bg) 1996-08-30
AU710235B2 (en) 1999-09-16
PL312546A1 (en) 1996-08-05
SK13796A3 (en) 1996-10-02
HU9600227D0 (en) 1996-03-28
DZ1986A1 (fr) 2002-10-15
HUP9600227A3 (en) 2000-03-28
EP0725064A1 (fr) 1996-08-07
UA35623C2 (uk) 2001-04-16
KR960031442A (ko) 1996-09-17

Similar Documents

Publication Publication Date Title
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP0693281A3 (fr) Formulations pharmaceutiques contenant de la fluoxétine
WO2002085299A3 (fr) Traitements therapeutiques recourant a l'application directe de compositions metalliques antimicrobiennes
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
TNSN96016A1 (fr) Utilisation de phenylcyclohexylcarboxamides
AU2845599A (en) Pharmaceutical compositions and their use
PT971717E (pt) Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
DE69331739D1 (de) Neuartige pharmazeutische verwendungen von krill-enzymen
WO2003100574A3 (fr) Appareils d'orthodontie et systemes et procedes de distribution d'appareils d'orthodontie
ME00578A (en) Use of gastrointestinal lipase inhibitors
MX9602973A (es) Uso de un antagonista de bradiquinina en una composicion, cosmetica, farmaceutica o dermatologica y la composicion obtenida.
PT1492773E (pt) Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
GB9505082D0 (en) Medicament